Zacks Investment Research upgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a sell rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
MCRB has been the subject of a number of other research reports. Seaport Global Securities reissued a buy rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald reissued a buy rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. ValuEngine raised shares of Seres Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 1st. BidaskClub raised shares of Seres Therapeutics from a hold rating to a buy rating in a research report on Tuesday, July 25th. Finally, Citigroup Inc. started coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They issued a positive rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $18.00.
Seres Therapeutics (NASDAQ:MCRB) opened at $9.41 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.22. The company had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The firm’s quarterly revenue was up 76.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.46) earnings per share. analysts expect that Seres Therapeutics will post -2.34 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/seres-therapeutics-inc-mcrb-rating-increased-to-hold-at-zacks-investment-research/1782901.html.
A number of institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC purchased a new stake in Seres Therapeutics in the third quarter valued at approximately $170,000. Perceptive Advisors LLC purchased a new stake in Seres Therapeutics in the third quarter valued at approximately $2,165,000. Schwab Charles Investment Management Inc. grew its holdings in Seres Therapeutics by 12.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock valued at $1,657,000 after purchasing an additional 11,743 shares during the period. Schroder Investment Management Group purchased a new stake in Seres Therapeutics in the third quarter valued at approximately $1,088,000. Finally, JPMorgan Chase & Co. grew its holdings in Seres Therapeutics by 39.9% in the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after purchasing an additional 106,479 shares during the period. Hedge funds and other institutional investors own 74.77% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with our FREE daily email newsletter.